福建省耐多药结核分枝杆菌对吡嗪酰胺的耐药水平与基因型特征分析

doi:10.3969/j.issn.1000-6621.2018.12.017

摘要/Abstract

摘要：

目的了解福建省耐多药结核分枝杆菌(MDR-MTB)对吡嗪酰胺(PZA)的耐药水平及基因型分布情况,分析PZA耐药水平及基因型之间的关系。方法收集2007—2008年和2010—2011年福建省耐药监测点共119株MDR-MTB临床分离株,采用WHO推荐的方法进行耐药性检测,应用间隔区寡核苷酸分型技术(Spoligotyping)进行基因分型,对分型结果上传至SpolDB4.0数据库,并进行聚类分析。结果 119株MDR-MTB菌株对PZA的耐药率为36.97%(44/119)。耐PZA菌株对链霉素(Sm)的耐药率为70.45%(31/44),高于PZA敏感菌株对Sm的耐药率[50.67%(38/75)],差异有统计学意义(χ ²=4.45,P=0.035);耐PZA菌株对乙胺丁醇(EMB)的耐药率为81.82%(36/44),高于PZA敏感菌株对EMB的耐药率[52.00%(39/75)],差异有统计学意义(χ ²=1.58,P=0.001)。北京基因型菌株占67.23%(80/119);非北京基因型菌株占32.77%(39/119),共有16个基因型(含8个新发现的基因型),其中常见的是H家族(含H和H3)和T家族(含T1、T2、T3和T5)。北京基因型菌株对PZA的耐药率(38.75%,31/80)与非北京基因型菌株对PZA的耐药率(33.33%,13/39)间差异无统计学意义(χ ²=0.33,P=0.566)。结论福建省耐多药结核病患者临床分离株对PZA耐药的问题应引起重视,对PZA耐药与对Sm和EMB耐药有关;MDR-MTB菌株主要为北京基因型,北京基因型与非北京基因型菌株对PZA的耐药率未见差异。

关键词: 分枝杆菌, 结核, 结核, 抗多种药物性, 吡嗪酰胺, 基因型

Abstract:

Objective In order to detect the phenotypic pyrazinamide (PZA) resistance and the genotypic distribution of MDR Mycobacterium tuberculosis (MTB) isolates from Fujian Province, and analyze the correlation between PZA resistance and genotype.Methods A total of 119 MDR-MTB strains were collected from the drug resistant surveillance sites in Fujian Province among 2007-2008 and 2010-2011. The drug susceptibility test (DST) of PZA recommended by WHO was conducted. Genotyping was performed by using Spoligotyping, and the results were uploaded to SpolDB 4.0 database for cluster analysis.Results The PZA resistant rate of 119 MDR-MTB strains was 36.97% (44/119). The streptomycin (Sm) resistant rate of PZA resistant strains (70.45%, 31/44) was higher than that of PZA sensitive strains (50.67%, 38/75), and the difference was statistically significant (χ ²=4.45, P=0.035). The ethambutol (EMB) resistant rate of PZA resistant strains (81.82%, 36/44) was higher than that of PZA sensitive strains (52.00%, 39/75), and the difference was statistically significant (χ ²=1.58, P=0.001). Beijing genotype strains accounted for 67.23% (80/119). Non Beijing genotype strains (32.77%, 39/119) had 16 genotypes including 8 new genotypes, the most common genotypes of which were H family containing H and H3 and T family containing T1, T2, T3 and T5. The PZA resistant rate of Beijing genotypic strains was 38.75% (31/80), and that of non Beijing genotypic strains was 33.33% (13/39); there was no significant difference in PZA resistant rate (χ ²=0.33, P=0.566). Conclusion We should pay attention to the problem about PZA resistance of MDR-MTB strains in Fujian Province. The resistance to PZA is related to the resistance to Sm and EMB. Beijing genotype is mainly prevalent in Fujian Province, and there is no significant difference in the PZA rate between Beijing genotypic strains and non Beijng genotypic strains.

Key words: Mycobacterium tuberculosis, Tuberculosis, multidrug-resistant, Pyrazinamide, Genotype

林淑芳,魏淑贞,赵永,林建,林勇明. 福建省耐多药结核分枝杆菌对吡嗪酰胺的耐药水平与基因型特征分析[J]. 中国防痨杂志, 2018, 40(12): 1330-1334. doi: 10.3969/j.issn.1000-6621.2018.12.017

LIN Shu-fang,WEI Shu-zhen,ZHAO Yong,LIN Jian,LIN Yong-ming.. Phenotypic pyrazinamide resistance and genotypic characteristics among multidrug-resistant Mycobacterium tuberculosis isolates in Fujian Province[J]. Chinese Journal of Antituberculosis, 2018, 40(12): 1330-1334. doi: 10.3969/j.issn.1000-6621.2018.12.017

图/表 1

参考文献 27

[1]	Ibrahim M, Andries K, Lounis N , et al. Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis. Antimicrob Agents Chemother, 2007,51(3):1011-1015. doi: 10.1128/AAC.00898-06 URL pmid: 17178794
[2]	Tasneen R, Tyagi S, Williams K , et al. Enhanced bactericidal activity of rifampin and/or pyrazinamide when combined with PA-824 in a murine model of tuberculosis. Antimicrob Agents Chemother, 2008,52(10):3664-3668. doi: 10.1016/S0167-8655(00)00032-5 URL pmid: 18694943
[3]	Diacon AH, Donald PR, Pym A , et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother, 2012,56(6):3271-3276. doi: 10.1128/AAC.06126-11 URL pmid: 22391540
[4]	Whitfield MG, Soeters HM, Warren RM , et al. A global perspective on pyrazinamide resistance: systematic review and meta-analysis. PLoS One, 2015,10(7):e0133869. doi: 10.1371/journal.pone.0133869 URL pmid: 4517823
[5]	Kam KM, Yip CW, Tse LW , et al. Utility of mycobacterial interspersed repetitive unit typing for differentiating multidrug-resistant Mycobacterium tuberculosis isolates of the Beijing family. J Clin Microbiol, 2005,43(1):306-313. doi: 10.1128/JCM.43.1.306-313.2005 URL pmid: 15634987
[6]	Lillebaek T, Andersen AB, Dirksen A , et al. Mycobacterium tuberculosis Beijing genotype. Emerg Infect Dis, 2003,9(12):1553-1557.
[7]	Glynn JR, Whiteley J, Bifani PJ , et al. Worldwide occurrence of Beijing/W strains of Mycobacterium tuberculosis: a systematic review. Emerg Infect Dis, 2002,8(8):843-849.
[8]	Gori A, Bandera A, Marchetti G , et al. Spoligotyping and Mycobacterium tuberculosis. Emerg Infect Dis, 2005,11(8):1242-1248.
[9]	World Health Organization , International Union Against Tuberculosis and Lung Diseases. Guidelines for surveillance of drug resistance in tuberculosis. Geneva: World Health Organi-zation, 1997.
[10]	World Health Organization . Policy guidance on drug susceptibility testing (DST) of second line antituberculosis drug. Geneva: World Health Organization, 2008: 11. URL pmid: 26290924
[11]	Viana-Niero C, Gutierrez C, Sola C , et al. Genetic diversity of Mycobacterium africanum clinical isolates based on IS6110-restriction fragment length polymorphiSm analysis, spoligotyping, and variable number of tandem DNA repeats. J Clin Microbiol, 2001,39(1):57-65. doi: 10.1128/JCM.39.1.57-65.2001 URL pmid: 87680
[12]	Brudey K, Driscoll JR, Rigouts L , et al. Mycobacterium tuberculosis complex genetic diversity: mining the fourth international spoligotyping database (SpolDB4) for classification, population genetics and epidemiology. BMC Microbiol, 2006,6:23. doi: 10.1186/1471-2180-6-23 URL pmid: 1468417
[13]	Weniger T, Krawczyk J, Supply P , et al. MIRU-VNTRplus: a web tool for polyphasic genotyping of Mycobacterium tuberculosis complex bacteria. Nucleic Acids Res, 2010,38(Web Server issue):W326-W331.
[14]	Xu P, Wu J, Yang C , et al. Prevalence and transmission of pyrazinamide resistant Mycobacterium tuberculosis in China. Tuberculosis (Edinb), 2016,98:56-61.
[15]	Kurbatova EV, Cavanaugh JS, Dalton T , et al. Epidemiology of pyrazinamide-resistant tuberculosis in the United States, 1999—2009. Clin Infect Dis, 2013,57(8):1081-1093. doi: 10.1093/cid/cit452 URL pmid: 4578633
[16]	Gu Y, Yu X, Jiang G , et al. Pyrazinamide resistance among multidrug-resistant tuberculosis clinical isolates in a national referral center of China and its correlations with pncA, rpsA, and panD gene mutations. Diagn Microbiol Infect Dis, 2016,84(3):207-211. doi: 10.1016/j.diagmicrobio.2015.10.017 URL pmid: 26775806
[17]	Pang Y, Zhu D, Zheng H , et al. Prevalence and molecular characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates from Southern China. BMC Infect Dis, 2017,17(1):711. doi: 10.1186/s12879-017-2761-6 URL pmid: 29110640
[18]	Alame-Emane AK, Xu P, Pierre-Audigier C , et al. Pyrazinamide resistance in Mycobacterium tuberculosis arises after rifa-mpicin and fluoroquinolone resistance. Int J Tuberc Lung Dis, 2015,19(6):679-684.
[19]	周银发, 张山鹰, 魏淑贞 , 等. 福建省耐多药结核分枝杆菌对吡嗪酰胺耐药性的研究. 结核病与肺部健康杂志, 2018,7(2):123-127.
[20]	梁庆福, 郑金凤, 陈求扬 , 等. 218例涂阳肺结核吡嗪酰胺耐药情况分析. 中国人兽共患病学报, 2012,28(10):1000-1002. doi: 10.3969/cjz.j.issn.1002-2694.2012.10.008 URL
[21]	Han SJ, Song T, Cho YJ , et al. Complete genome sequence of Mycobacterium tuberculosis K from a Korean high school outbreak, belonging to the Beijing family. Stand Genomic Sci, 2015,10:78.
[22]	Maeda S, Wada T, Iwamoto T , et al. Beijing family Mycobacterium tuberculosis isolated from throughout Japan: phylogeny and genetic features. Int J Tuberc Lung Dis, 2010,14(9):1201-1204.
[23]	刘飞鹰, 刘志广, 王喜文 , 等. Spoligotyping对广西地区208株结核分枝杆菌临床分离株的基因分型. 中国人兽共患病学报, 2007,23(12):1226-1230. doi: 10.3969/j.issn.1002-2694.2007.12.015 URL
[24]	王晓萌, 吕冰, 柳正卫 , 等. Spoligotyping和MLVA用于71株浙江省结核分枝杆菌临床分离株基因分型的初步研究. 中国人兽共患病学报, 2008,24(12):1090-1094. doi: 10.3969/j.issn.1002-2694.2008.12.002 URL
[25]	Li Y, Cao X, Li S , et al. Characterization of Mycobacterium tuberculosis isolates from Hebei, China: genotypes and drug susceptibility phenotypes. BMC Infect Dis, 2016,16:107.
[26]	逄宇, 夏辉, 姜广路 , 等. 中国结核分枝杆菌寡核苷酸基因分型及其耐药性分析. 中华检验医学杂志, 2011,34(11):1023-1028. doi: 10.3760/cma.j.issn.1009-9158.2011.11.014 URL
[27]	王胜芬, 赵雁林, 黄海荣 , 等. 结核分枝杆菌北京基因型菌株与耐药表型的关系. 中国医学科学院学报, 2009,31(4):427-431. doi: 10.3881/j.issn.1000-503X.2009.04.009 URL

药敏情况	非北京基因型 [株(构成比,%)]	北京基因型 [株(构成比,%)]	合计 (株)	χ²值	P值
PZA				0.33	0.566
敏感	26(66.67)	49(61.25)	75
耐药	13(33.33)	31(38.75)	44
Sm				1.07	0.301
敏感	19(48.72)	31(38.75)	50
耐药	20(51.28)	49(61.25)	69
EMB				0.33	0.566
敏感	13(33.33)	31(38.75)	44
耐药	26(66.67)	49(61.25)	75